Clinical Trial Update: Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C [Phase 3]

View source ↗

Summary

Completed Phase 3 trial evaluating irbesartan for reducing hepatic fibrosis in chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Irbesartan (irbesartan)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED